Matrixyl (Palmitoyl Pentapeptide-4, also known as pal-KTTKS) is one of the most successful and widely used cosmetic peptides, developed by Sederma (now part of Croda International). The pentapeptide KTTKS was originally identified as a fragment of collagen type I propeptide — a natural signal (matrikine) produced during collagen turnover that tells fibroblasts to produce more collagen. Adding a palmitoyl (C-16 fatty acid) chain dramatically improved the peptide's skin penetration and stability. Clinical studies have shown that Matrixyl can reduce wrinkle depth by up to 44% over 4 months of twice-daily application. It stimulates production of multiple extracellular matrix components including collagen types I, III, and IV, fibronectin, and elastin. Matrixyl has been incorporated into thousands of cosmetic products globally and has spawned a family of related peptides including Matrixyl 3000 (palmitoyl tetrapeptide-7 + palmitoyl oligopeptide) and Matrixyl Synthe'6.
Key Data
Mechanism of Action
Matrixyl mimics a collagen breakdown fragment (matrikine) that signals fibroblasts to increase production of collagen types I, III, and IV, fibronectin, elastin, and other extracellular matrix components. The palmitoyl chain enhances skin penetration.
Reported Benefits
All information is presented for Research Use Only (RUO). Not medical advice.